https://mindmedicinelaw.com/briefing/ketamine-for-depression-in-cancer-patients-systematic-review-insights-20260529-8216The Psychedelic Journalen2026-05-30T15:04:56.922663+00:00Ketamine for Depression in Cancer Patients: Systematic Review Insightsketamine, depression, cancer patients, systematic review, rapid-acting antidepressant, treatment-resistant depression, clinical trials, long-term safety, psycho-oncology, dosing strategieshttps://mindmedicinelaw.com/briefing/pharmacokinetics-of-psychedelics-new-insights-from-systematic-review-20260529-8202The Psychedelic Journalen2026-05-30T15:04:47.420844+00:00Pharmacokinetics of Psychedelics: New Insights from Systematic Reviewpsychedelic pharmacokinetics, LSD, psilocybin, DMT, mescaline, 5-MEO-DMT, clinical trials, serotonergic psychedelics, dosing regimens, safety profileshttps://mindmedicinelaw.com/briefing/ketamine-for-depression-in-cancer-systematic-review-insights-20260529-8215The Psychedelic Journalen2026-05-30T15:04:37.876973+00:00Ketamine for Depression in Cancer: Systematic Review Insightsketamine, depression, cancer patients, systematic review, rapid antidepressant, clinical trials, mental health, oncology, treatment adherence, long-term safetyhttps://mindmedicinelaw.com/briefing/meta-analysis-reveals-mania-risks-in-psychedelic-use-20260529-8235The Psychedelic Journalen2026-05-30T15:04:28.355948+00:00Meta-analysis Reveals Mania Risks in Psychedelic Usepsychedelic research, hypomania risks, mania risks, clinical trials, patient screening, psychedelic-assisted therapy, serotonin receptors, mood disorders, therapeutic guidelines, neurochemical pathwayshttps://mindmedicinelaw.com/briefing/colorado-expands-natural-medicine-health-act-with-ibogaine-20260529-8281The Psychedelic Journalen2026-05-30T15:04:20.676355+00:00Colorado Expands Natural Medicine Health Act with Ibogainecolorado, natural medicine health act, ibogaine, psychedelic policy, substance use disorder, psychedelic research, clinical trials, regulation, therapeutic use, safety concernshttps://mindmedicinelaw.com/briefing/va-initiates-mdma-therapy-trial-for-ptsd-and-alcohol-use-20260529-8188The Psychedelic Journalen2026-05-30T15:04:10.350755+00:00VA Initiates MDMA Therapy Trial for PTSD and Alcohol UseMDMA therapy, VA clinical trial, PTSD treatment, alcohol use disorder, psychedelic research, veterans mental health, federal agency involvement, psychedelic-assisted therapyhttps://mindmedicinelaw.com/briefing/review-of-ketamine-pharmacokinetics-published-by-ncbi-20260529-8098The Psychedelic Journalen2026-05-29T22:04:46.883186+00:00Review of Ketamine Pharmacokinetics Published by NCBIketamine pharmacokinetics, intramuscular administration, clinical dosing strategies, psychiatric treatment, therapeutic outcomes, metabolism of ketamine, clinical research, psychedelic medicine, personalized medicine, public health implicationshttps://mindmedicinelaw.com/briefing/pharmacokinetics-of-psychedelics-implications-for-clinical-use-20260529-8093The Psychedelic Journalen2026-05-29T22:03:58.142038+00:00Pharmacokinetics of Psychedelics: Implications for Clinical Usepsychedelic pharmacokinetics, serotonergic psychedelics, clinical trials, LSD, psilocybin, DMT, therapeutic use, FDA guidelines, safety data, personalized medicinehttps://mindmedicinelaw.com/briefing/va-launches-mdma-trial-psilocybin-shows-lasting-effects-20260529-8122The Psychedelic Journalen2026-05-29T22:03:48.161550+00:00VA Launches MDMA Trial; Psilocybin Shows Lasting EffectsMDMA trial, psilocybin effects, Veterans Affairs, PTSD treatment, psychedelic therapy, mental health, clinical trials, antidepressant effects, psychedelic research, federal policyhttps://mindmedicinelaw.com/briefing/psilocybin-induced-syncope-in-clinical-trials-a-case-study-20260528-7887The Psychedelic Journalen2026-05-29T22:04:10.378207+00:00Psilocybin-Induced Syncope in Clinical Trials: A Case Studypsilocybin, neurocardiogenic syncope, clinical trials, cardiovascular monitoring, adverse events, psychedelic research, FDA approval, safety protocols, autonomic arousal, hypotensive eventshttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-in-advanced-alzheimer-s-a-case-study-20260528-7888The Psychedelic Journalen2026-05-29T15:06:37.720719+00:00Psilocybin's Potential in Advanced Alzheimer's: A Case Studypsilocybin, Alzheimer's disease, psychedelic research, neuromodulation, clinical trials, neurodegenerative diseases, functional improvement, case study, advanced dementia, brain plasticityhttps://mindmedicinelaw.com/briefing/5-ht2b-receptor-safety-potential-in-depression-therapy-20260528-7890The Psychedelic Journalen2026-05-29T15:05:59.277474+00:005-HT2B Receptor: Safety & Potential in Depression Therapy5-HT2B receptor, depression treatment, cardiac risks, treatment-resistant depression, antidepressant development, central nervous system, peripheral agonism, valvular heart disease, serotonergic psychedelics, biomarker monitoringhttps://mindmedicinelaw.com/briefing/esketamine-s-role-in-elderly-lung-surgery-recovery-clinical-insights-20260528-7900The Psychedelic Journalen2026-05-29T15:05:49.389681+00:00Esketamine's Role in Elderly Lung Surgery Recovery: Clinical Insightsesketamine, elderly patients, lung cancer surgery, postoperative recovery, multimodal anesthesia, opioid reduction, clinical trial, pain managementhttps://mindmedicinelaw.com/briefing/esketamine-adverse-events-in-depression-global-meta-analysis-20260528-7889The Psychedelic Journalen2026-05-29T15:05:39.563437+00:00Esketamine Adverse Events in Depression: Global Meta-Analysisesketamine, treatment-resistant depression, adverse events, dose-dependent risks, precision dosing, geographic variations, clinical trials, meta-analysis, psychiatric treatment, depression therapyhttps://mindmedicinelaw.com/briefing/psilocybin-induced-syncope-implications-for-clinical-trials-20260528-7788The Psychedelic Journalen2026-05-28T22:04:42.953641+00:00Psilocybin-Induced Syncope: Implications for Clinical Trialspsilocybin, neurocardiogenic syncope, clinical trials, psychedelic therapy, safety protocols, cardiovascular effectshttps://mindmedicinelaw.com/briefing/va-s-mdma-assisted-therapy-trial-implications-for-ptsd-treatment-20260528-7804The Psychedelic Journalen2026-05-28T22:04:32.637123+00:00VA's MDMA-Assisted Therapy Trial: Implications for PTSD TreatmentMDMA-assisted therapy, Veterans Affairs, PTSD treatment, psychedelic research, mental health policy, clinical trials, government agencies, psychedelic integration, veteran mental health, FDA approvalhttps://mindmedicinelaw.com/briefing/california-2026-psychedelics-ballot-measure-explained-20260528The Psychedelic Journalen2026-05-28T20:10:28.017457+00:00California 2026 Psychedelics Ballot Measure: Explainercalifornia 2026 psychedelics ballot measure, california psilocybin ballot initiative 2026, scott wiener sb 1012 psychedelics, california sb 751 psilocybin, california psilocybin legalization 2026, california psychedelic ballot measure, mdma legalization california ballothttps://mindmedicinelaw.com/briefing/sert-blockade-diminishes-4-meo-mipt-s-psychedelic-effects-20260527-7854The Psychedelic Journalen2026-05-29T22:04:35.602266+00:00SERT Blockade Diminishes 4-MeO-MiPT's Psychedelic Effects4-MeO-MiPT, SERT blockade, 5-HT2A agonist, psychedelic research, therapeutic psychedelics, serotonin transporter, clinical trials, pharmacology, psychoactive profiles, neurosciencehttps://mindmedicinelaw.com/briefing/psychedelics-antidepressant-mechanisms-via-gpcrs-20260527-8099The Psychedelic Journalen2026-05-29T22:04:19.002036+00:00Psychedelics' Antidepressant Mechanisms via GPCRspsychedelics, G Protein-Coupled Receptors, antidepressant effects, clinical research, biochemical pathways, depression treatment, psilocybin, LSD, mental health, drug developmenthttps://mindmedicinelaw.com/briefing/ketamine-focus-therapy-gains-popularity-in-miami-20260527-7806The Psychedelic Journalen2026-05-28T22:04:51.531361+00:00Ketamine 'Focus Therapy' Gains Popularity in Miamiketamine therapy, mental health, focus therapy, Miami, alternative treatments, public health, market dynamics, men's healthhttps://mindmedicinelaw.com/briefing/ukraine-s-exploration-of-psychedelic-therapy-for-ptsd-20260525-7860The Psychedelic Journalen2026-05-29T15:06:22.758034+00:00Ukraine's Exploration of Psychedelic Therapy for PTSDpsychedelic therapy, PTSD, Ukraine, clinical trials, legislative amendments, international practices, mental health, veterans, drug-control laws, psychedelic-assisted psychotherapyhttps://mindmedicinelaw.com/briefing/psychedelic-therapy-s-potential-in-ukraine-legal-and-clinical-impacts-20260525-7859The Psychedelic Journalen2026-05-29T15:06:12.177783+00:00Psychedelic Therapy's Potential in Ukraine: Legal and Clinical Impactspsychedelic therapy, PTSD, Ukrainian veterans, psilocybin, MDMA, legal framework, clinical trials, mental health, Australia, Switzerlandhttps://mindmedicinelaw.com/briefing/spleen-gut-brain-axis-a-new-frontier-in-depression-treatment-20260524-7578The Psychedelic Journalen2026-05-28T22:05:00.001248+00:00Spleen-Gut-Brain Axis: A New Frontier in Depression Treatmentspleen-gut-brain axis, depression treatment, immune modulation, gut microbiota, neuroinflammation, precision psychiatry, natural compounds, systemic inflammation, treatment-resistant depressionhttps://mindmedicinelaw.com/briefing/l-fame-eeg-dataset-advances-meditation-research-20260521-7546The Psychedelic Journalen2026-05-28T22:05:08.606399+00:00L-FAME EEG Dataset Advances Meditation ResearchL-FAME dataset, EEG meditation research, neural effects of meditation, cognitive state decoding, machine learning in meditation, clinical applications of meditation, meditation techniques, longitudinal meditation study